Key facts
- It has raised $97.4M across 2 recorded rounds; the latest was Later Stage VC ($50.3M) in Sep 2024.
- Notable investors include Johnson & Johnson JJDC, SV Health Investors, Deerfield Management, S3 Ventures, Lumira Ventures — 7 tracked in total.
- SpectraWAVE has filed 3 Form Ds with the SEC since 2019, most recently Oct 2024 ($50.3M sold to 33 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for SpectraWAVE
Funding rounds
2 roundsAbout SpectraWAVE
Developer of an intravascular imaging technology designed to improve coronary artery disease outcomes with photonics. The company's system is a state-of-the-art integration of proven imaging technologies and aids in optimal stent intervention by identifying patients and plaques at risk of future coronary adverse events, enabling interventional cardiologists to access optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD).
- Sector
- Healthcare
- HQ
- Bedford, MA, United States
- Founded
- 2017
- Employees
- 74
- Website
- spectrawave.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
SpectraWAVE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SpectraWAVE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SpectraWAVE in its N-PORT filings yet. We sweep new filings monthly.